PMK L-Arginine 500 mg
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| L-arginine Source : Chlorhydrate de L-arginine | 0.5 g | Not calculated |
| L-arginine Source : Monohydrochlorure de L-arginine | 0.5 g | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Stéarate de magnésium, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 4 Capsule | 3 days |
Uses authorised in Canada
L-Arginine is a non-essential amino acid that is involved in protein synthesis. May help support a modest improvement in exercise capacity in individuals with stable cardiovascular diseases (CVD).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you have had a heart attack/myocardial infarction.
Product record
- Other names
- L-Arginine 500 mg
- Licence holder
- PMK Federal Regulatory Consultants Ltd.
- NPN or DIN-HM
- 80043121
- Status
- Active licence
- Licence date
- 24 June 2013
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
Source
Official Health Canada record, licence 80043121
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.